Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel
Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA, B F. Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treatment Reviews 2008, 34: 223-230. PMID: 18234424, PMCID: PMC2651678, DOI: 10.1016/j.ctrv.2007.11.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleFilgrastimFollow-Up StudiesGranulocyte Colony-Stimulating FactorHumansLymphatic MetastasisMiddle AgedPaclitaxelPilot ProjectsRecombinant ProteinsConceptsG-CSF supportGrowth factor supportRelapse-free survivalClinical outcomesDose levelsG-CSFFactor supportConventional doseClinical trialsBreast cancerNode-positive invasive breast cancerNode-positive breast cancer patientsAcute treatment-related toxicityHematopoietic growth factor supportOperable primary breast cancerAdjuvant chemotherapy regimenDose-intensified regimenDose-intensive regimensEarly study withdrawalNode-positive patientsTreatment-related toxicityHormone receptor statusInvasive breast cancerOverall survival ratePrimary breast cancer